Aust Business Solutions

Boehringer Ingelheim and Circle Pharma, Inc. are tackling one of the most complex challenges in #CancerTreatment with a groundbreaking approach. Their recent collaboration, valued at up to $607 million in milestone payments, aims to develop a first-in-class cyclin inhibitor that targets uncontrolled cell growth—a key factor in many cancers. By utilizing Circle Pharma's innovative macrocycle platform, this partnership is poised to address difficult-to-treat tumors, offering new hope for patients and advancing the boundaries of precision medicine. Leading Circle Pharma, Inc.’s strategic vision is David J. Earp, JD, PhD, CEO, with Paul Park, Chief Business Officer, driving business development efforts. Together, they are shaping the future of cancer therapeutics with a focus on delivering transformative solutions for unmet clinical needs. #Biotech #CancerResearch #PrecisionMedicine #Innovation #Oncology #DrugDevelopment #Pharma #MacrocycleTherapies #LifeSciences

Samsung Biologics continues to grow with the acquisition of another Asian company, valued at $1.2 B USD! https://lnkd.in/ddpR2D4f #manufacturing #pharmaceuticalindustry #deals #business #CDMO

We will see you in #Boston next week for #PODD2024! https://lnkd.in/gQ_wSyBb PODD: Partnership Opportunities in Drug Delivery Community News #DDS #LNP #PNP #DrugDelivery

Nanoform's, Christian Jones, will moderate the panel "Balancing Between Concentration and Volume when Developing Patient-Centric Biologics" at #PODD2024. Panelists will discuss how they facilitate partnerships between drug product development, device engineering and clinical study teams to determine how to balance concentration and volume and develop optimal devices for delivery and commercialization. Specifically: - Impact on increasing concentration of drugs on deliverability - Technical feasibility of manufacturing larger volume devices - Patient tolerability and human factors that impact patient adherence Learn more at: poddconference.com #PODD #DrugDevelopment #DrugDelivery #Patients #biologics #deviceengineering #LargeVolumeDevices

Looking forward to seeing people at #PODD2024, Partnership Opportunities in Drug Delivery, October 28-29. This year’s agenda is incredibly interesting and diverse with presentations and panel discussions on pipeline trends, payer perspectives and the most recent innovations in drug delivery technologies. 

Announcing the companies presenting on the excipient innovation track at #PODD2024 • Evonik • MilliporeSigma • DelAQUA Pharmaceuticals • Gaylord Chemical Company, LLC • Lipoid • #PendantBiosciences • Secant Group • Asahi Kasei Plastics North America, Inc. • Vesselon • Biotts Learn more at PODDconference.com #DrugDelivery #DrugDevelopment #excipient #PODD

I am excited to attend #PODD (Partnership Opportunities in Drug Delivery) this October 28-29th in #Boston! We are looking forward to acting as an old fashion phone operator at the 14th Annual Meeting, connecting Biopharmas/Biotechs, CDMOs, and Investors we know to help advance their innovative technologies. I also hope to meet new companies with emerging tech. If you would like to chat before, during, or after the event, feel free to reach out. See you there! #biotech #biopharma #CDMO #investors #PE #VC #lipids #lipidnanoparticles #LNP #liposomes #PNP #DDS #innovation #business #pharma #pharmaceuticalindustry #pharmaceuticalmanufacturing PODD: Partnership Opportunities in Drug Delivery Community News

This article touches on:  ⚪ Lipid selection and classification (Drug Product) ⚪ RNA impurities and classification (Drug Substance) ⚪ mRNA-LNP physical characterization requirements & suggestions ⚪ Varying regulatory authority expectations https://lnkd.in/eYStDqM2 #LNP #LipidNanoparticle #Liposome #RNA #nucleicacid #regulatory #regulatoryaffairs #manufacturing #pharmaceuticalmanufacturing #pharmaceuticalindustry #Pharma #FDA #EMA #NMPA #DP #DS #CDMO #CRO

I am excited to speak at the Cytiva RNA-LNP Virtual Summit on 19-Sep-24! Come join the RNA-LNP Virtual Summit to explore the latest advancements in RNA-LNP manufacturing and its expanding applications through a series of engaging presentations, an insightful panel discussion, and interactive Q&A sessions. Click here to register: https://lnkd.in/eAEV8-UG #RNA #LNP #LNPs #Liposomes #liposome #celltherapy #genetherapy #geneediting #biotech #biopharma #pharma #education #drugdevelopment #news #business #businessintelligence

Candid Therapeutics' $370M debut is a significant move in the #biotech industry, attracting attention from top-tier life science investors like Venrock, Fairmount Funds Management LLC, TCGX and venBio. This funding will fuel the clinical development of its two lead candidates, CND106 and CND261, which focus on treating autoimmune diseases by targeting B-cell populations. With Ken Song at the helm, Candid benefits from a leadership team with a proven track record of high-value exits, such as Song’s leadership at RayzeBio, which was sold to Bristol Myers Squibb for $4.1 billion earlier this year. The company’s strategy of using bispecific T-cell engager (TCE) antibodies represents a cutting-edge approach, positioning it to potentially surpass industry standards set by drugs like Humira. With both candidates already having shown promising Phase 1 results, this venture could redefine how autoimmune diseases are treated, setting a new paradigm in scalable and patient-friendly therapies. The deal not only involves significant players like Foresite Capital but also brings in expertise from companies like Vignette Bio and Two Rivers through a strategic merger. These connections reinforce the importance of collaboration and experienced leadership in advancing biotech innovations. Bernie Huyghe David Luo Jessica Rearden, PhD, RN Jeremy Lim Jim Tananbaum Aaron Royston, M.D. Cariad Chester Michael Rome #innovation #pharmaceuticals #venturecapital #investment